# SciBrunch Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/scibrunch-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.scibrunch.com
- Total disclosed funding: $28M
- Latest round: Angel (Jun 5, 2025)
- Investors on record: 4

## About

Based in Shanghai, China and founded in 2024, Shanghai SciBrunch Therapeutics Co., Ltd., trading as SciBrunch Therapeutics, is a pharmaceutical technology company that provides small molecule antitumor drugs. In January 2026, SciBrunch Therapeutics raised over USD 35 million in Pre-Series A funding led by new investor HighLight Capital, with participation from new investors Suzhou Xincheng Private Equity Fund Management, returning investors Elikon Venture, LongRiver Investments, BioTrack Capital and Hankang Capital.
The company specializes in the iterative innovation of these drugs. The company uses a new perspective to identify clinically validated targets and proactively designs differentiated product performance to create a competitive product pipeline.
The company generates revenue by doing R&D and providing small molecule anti-cancer drugs.
The Pre-series A funding raised in January 2026 will be primarily used to accelerate the clinical development of its core pipeline SPR1020 and advance the IND development of a new generation of innovative molecular glue-type RAS inhibitors, explore the clinical potential in refractory tumors with RAS mutations (colorectal cancer, pancreatic cancer, non-small cell lung cancer, etc.), and comprehensively empowering the creation of preferred treatment options for RAS-driven cancers.

## Funding rounds

- Angel, Jun 5, 2025, $28M — BioTrack Capital, Hankang Capital, Elikon Venture, LongRiver Investments

## Investors

- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Angel
- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Angel
- Elikon Venture (https://capitalatlas.ai/funds/elikon-venture) — Angel
- LongRiver Investments (https://capitalatlas.ai/funds/longriver-investments) — Angel